Clinova has developed Covaflu FFP2 disposable face masks to prevent harmful particles from entering your lungs by providing FFP2 particle filtration. Covaflu protects healthy individuals, by preventing person to person airborne contamination and filters out approximately 94% of droplets, which are 0.3 microns in size and over; the majority of sneezed droplets contaminated with influenza [...]
Clinova is co-developing a new generation liquid pain killer encapsulating Ibuprofen and Paracetamol to help treat mild-to-moderate pain. Clinova is currently completing phase 3 studies of PI and the product is expected to be launched in 2014.
Clinova is developing a innovative indigestion remedy encapsulating a natural active as its principal ingredient. The product aims to help alleviate dyspepsia and other disorders of the digestive tract. The company is validating a liquid formulation, which is undergoing pre-formulation development.
Clinova is developing a revolutionary insect repellent patch to help reduce Mosquito bites. Clinova has proven the effectiveness of the anti-mosquito patch for apparel treatment in laboratory tests with yellow fever mosquito’s (Aedes aegypti). Clinova is currently completing registration in a number of territories with UK launch due in 2013.
O.R.S is a soluble tablet that contains a scientifically balanced formula of glucose, electrolytes and essential minerals which when added to water may be used to replenish the body’s water and salts and thereby help to maintain a healthy fluid balance in adults and children. Clinova is presently launching O.R.S in 31 countries.